Inkef

Draupnir Bio intends to develop a new type of cholesterol-lowering medicine that prevents blood clots in the heart more effectively than the current medicine. The company is developing a platform for exploring the glycome to develop novel therapeutics, based on array technology, protein chemistry, and advanced carbohydrate chemistry. The company is able to synthesize, screen, and select highly potent and specific heparan sulfate glycomimetic drug candidates in cardiovascular, inflammatory, and infectious diseases.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

Provable Markets is a financial services company that offers market participants a secure, unified, and pragmatic access point for cash and synthetic equity finance trading. The company has developed an SEC registered Alternative Trading System (ATS) named Aurora. Provable Markets aims to create a paradigm shift in how financial markets operate, with a focus on transparency and solving some of the biggest challenges in the financial industry. The company has a community of passionate people working towards these goals.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Silverflow is a payment processing technology company based in Amsterdam, Netherlands, founded in 2019. The company offers a cloud-based payments platform that enables payment service providers (PSPs) to gain direct access to card networks. This innovative platform allows PSPs to enhance their services by instantly adding new functionalities and obtaining real-time insights into transaction fees. Additionally, Silverflow provides smart data directly from the networks, which helps payment providers serve their merchants more effectively. By streamlining data flow and utilizing basic application programming interfaces, Silverflow aims to improve agility, transparency, and security in global payment operations, benefiting not only PSPs but also merchants and acquirers.

NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.

Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Based in Cambridge, Massachusetts, the company utilizes proprietary platforms and biomarkers to create precision medicines targeting genetically validated disease-causing alterations. Its pipeline includes various treatments aimed at specific subtypes of ALS, such as therapies designed to restore dysfunctional cellular waste clearance, manage overactive neurons to prevent cell death, and eliminate toxic proteins. QurAlis aims to advance its antisense oligonucleotides and small molecule programs to address the most prevalent forms of ALS, ultimately working to halt disease progression and improve patient outcomes. The company was incorporated in 2016 and operates as a subsidiary of Q-State Biosciences, Inc.

Quantum Motion Technologies is focused on developing universal quantum computers utilizing silicon-based, CMOS-compatible processes. The company aims to address key challenges in quantum computing, such as fault tolerance and qubit redundancy, by creating scalable architectural technologies. By leveraging complementary metal-oxide semiconductor processing, Quantum Motion strives to achieve greater qubit density, enabling the construction of large-scale quantum systems. This approach not only enhances the performance of quantum computers but also assists clients in the quantum technology sector in overcoming significant errors and critical challenges in quantum information processing.

Happeo is a digital workplace platform that offers an advanced intranet solution for teams to manage knowledge and internal communications effectively. The platform features a template-based page builder, integrations, and a universal search functionality that simplifies access to various company tools. Happeo's user-friendly design makes it suitable for organizations of all sizes, with notable clients like Doctolib, GANT, and Marqeta utilizing its services to enhance team alignment and productivity. The platform supports internal communicators by managing calendars, files, conferencing, and projects, while also integrating with CRM and HR systems. Happeo aims to foster engagement and create a positive employee experience, achieving adoption rates that are three times higher than the industry average.

Baserow is a no-code, open-source database platform founded in 2021 by Bram Wiepjes and Olivier Maes. It allows non-technical teams to capture and organize data effectively, facilitating intelligent business insights and process automation. The platform enables users to manage essential business operations without the limitations often associated with traditional SaaS tools, such as data governance, scalability, and security concerns. Baserow provides a range of tools for creating flexible checklists, organizing collections, and managing customer contacts, along with various templates for diverse applications, from home improvement to inventory management. This empowers users to build custom applications without requiring prior coding experience.

Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.

ChannelEngine is a cloud-based platform that facilitates integration between sellers' systems and various international marketplaces and sales channels. By providing a comprehensive Software as a Service solution, it allows brands, distributors, and retailers to automate their order and return processes, thereby optimizing sales operations while enhancing efficiency and profitability. The platform features an advanced management suite and a robust partner ecosystem, empowering businesses to effectively manage their external sales and maximize their international sales potential. Through seamless integration, ChannelEngine aims to elevate the sales capabilities of its clients in the competitive e-commerce landscape.

Scenic Biotech is a biotechnology company focused on developing innovative genomics and immunotherapy technologies aimed at addressing severe diseases, including cancer and rare genetic disorders. The company's approach involves identifying genetic suppressors, which are genes that can counteract the effects of disease-causing mutations, thus serving as new drug targets. By leveraging its advanced technology, Scenic Biotech enables scientists to rapidly identify and validate these novel drug targets, facilitating the development of disease-modifying therapeutics. This targeted strategy not only enhances the understanding of genetic influences on diseases but also aims to improve treatment outcomes for affected patients.

TargED Biopharmaceuticals is a biotechnology company focused on developing innovative biological drugs aimed at enhancing the treatment of thrombosis. The company utilizes small antibodies, known as VhH, to deliver enzymes directly to the sites of thrombus, facilitating targeted thrombolysis. This approach allows for effective treatment regardless of the blood clot's composition, thereby enabling healthcare professionals to accelerate patient care and improve outcomes for those affected by thrombosis.

NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.

AmbAgon Therapeutics is a biotechnology company focused on developing small-molecule therapeutics for cancer treatment. The company specializes in research aimed at stabilizing the interactions of oncogenic proteins, thereby enhancing the activity of tumor-suppressing proteins. By targeting these proteins, AmbAgon Therapeutics seeks to address significant unmet clinical needs in oncology that conventional treatment methods have struggled to meet. Founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin, the company aims to provide innovative solutions in cancer care through its unique approach to drug development.

ViCentra, they like to keep things simple. ViCentra believe that if products are simple, look beautiful and deliver superb results, they’ll be more enjoyable to use and more likely to help people achieve great things. Creating brilliant products doesn’t end at the manufacturing line though – they also believe in the power of great customer experiences. From our offices in the Netherlands and UK, they’re creating healthcare products with this philosophy firmly in mind. They don’t design for patients – they design for people.

Silverflow is a payment processing technology company based in Amsterdam, Netherlands, founded in 2019. The company offers a cloud-based payments platform that enables payment service providers (PSPs) to gain direct access to card networks. This innovative platform allows PSPs to enhance their services by instantly adding new functionalities and obtaining real-time insights into transaction fees. Additionally, Silverflow provides smart data directly from the networks, which helps payment providers serve their merchants more effectively. By streamlining data flow and utilizing basic application programming interfaces, Silverflow aims to improve agility, transparency, and security in global payment operations, benefiting not only PSPs but also merchants and acquirers.

Shapeways, Inc. is a 3D printing marketplace and community that allows users to create, buy, and sell customized products across various categories, including art, fashion, home goods, gadgets, games, jewelry, DIY projects, miniatures, and gifts. Founded in 2008 and headquartered in New York, with additional offices in Eindhoven, Netherlands, and Seattle, Washington, Shapeways utilizes on-demand printing to ensure that each order is tailored to individual specifications. The platform not only facilitates the transformation of digital designs into physical products but also fosters a community where members can share ideas and access advanced 3D printing technology. By democratizing the creation process, Shapeways empowers users to launch their own businesses and sell products globally.

Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strong expertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in the development of non-coding RNA-based therapeutics aimed at treating and preventing heart disease, a leading cause of mortality in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a molecular master switch (microRNA) responsible for pathological changes in the heart resulting from stress or injury. By advancing innovative therapies, Cardior Pharmaceuticals aims to address significant health challenges associated with cardiovascular conditions.

Castor is an international health-tech company that provides a cloud-based clinical data platform designed to streamline the clinical trial process for researchers globally. Founded by CEO Derk Arts, MD, Ph.D., the platform is utilized by over 50,000 researchers in 90 countries, supporting more than 4,000 studies across diverse therapeutic areas, including diabetes, cardiovascular disease, rare diseases, infectious diseases, and oncology. Castor's platform facilitates the collection and analysis of extensive data from both traditional and remote trials, having reached significant milestones such as 180 million data points and 2 million enrolled patients. The company's mission is to make research data reusable, thereby enabling AI-driven clinical trials and enhancing the overall impact of data within the medical research community.

Urban Sports Club offers a flexible sports flatrate. The mission is to help people lead a more healthy and active lifestyle. Club members can choose from more than 50 types of sports – ranging from classic gym workout, swimming, yoga, or bouldering, to team sports, wellness and lots more – and more than 10.000 partner venues in Germany, France, Italy, Spain, Portugal and Belgium. Variety, flexible conditions as well as team sports and wellness are offered both for private customers and companies. Urban Sports GmbH was founded in 2012 by Moritz Kreppel and Benjamin Roth in Berlin, Germany. After two years of bootstrapping, the company secured an early-stage financing in 2015 and went on to acquire four of its German competitors, starting with Somuchmore in December, 2016. In January 2018, FITrate came on board, with INTERFIT following in December of the same year. OneFit joined the Urban Sports Club family in August of 2019.

Sentinels is an AI-powered startup specializing in transaction monitoring solutions for the financial industry. The company offers a cloud-based platform that enhances compliance efforts for fintech companies by providing data-driven insights to combat money laundering and other illegal activities. By optimizing anti-money laundering processes, Sentinels enables compliance experts to gain real-time, actionable information, thereby improving the effectiveness of their monitoring efforts.

Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Lengoo specializes in unlocking the potential of language data for enterprises through its advanced technology platform, HALOS. This platform enables organizations to build and operate custom language models at scale while maintaining high standards of IT security and intellectual property protection. For over five years, Lengoo has assisted global industry leaders and emerging companies in securely adopting artificial intelligence solutions. The company offers language intelligence applications, such as Flow, and a robust API that empower office workers with reliable virtual AI partners, enhancing organizational efficiency and supporting sustained growth.

ChannelEngine is a cloud-based platform that facilitates integration between sellers' systems and various international marketplaces and sales channels. By providing a comprehensive Software as a Service solution, it allows brands, distributors, and retailers to automate their order and return processes, thereby optimizing sales operations while enhancing efficiency and profitability. The platform features an advanced management suite and a robust partner ecosystem, empowering businesses to effectively manage their external sales and maximize their international sales potential. Through seamless integration, ChannelEngine aims to elevate the sales capabilities of its clients in the competitive e-commerce landscape.

EclecticIQ specializes in threat intelligence and cybersecurity solutions, offering technology and services that enhance the defense against cyber threats. The company develops platforms that integrate and analyze intelligence data from various sources, including open and commercial suppliers, as well as industry partnerships. This integration allows organizations to improve their detection, prevention, and response capabilities against adversaries. By embedding intelligence into cybersecurity frameworks, EclecticIQ aims to empower enterprises to effectively combat evolving cyber threats.

Silverflow is a payment processing technology company based in Amsterdam, Netherlands, founded in 2019. The company offers a cloud-based payments platform that enables payment service providers (PSPs) to gain direct access to card networks. This innovative platform allows PSPs to enhance their services by instantly adding new functionalities and obtaining real-time insights into transaction fees. Additionally, Silverflow provides smart data directly from the networks, which helps payment providers serve their merchants more effectively. By streamlining data flow and utilizing basic application programming interfaces, Silverflow aims to improve agility, transparency, and security in global payment operations, benefiting not only PSPs but also merchants and acquirers.

Salvia BioElectronics B.V., founded in 2017 and headquartered in Eindhoven, the Netherlands, focuses on developing bioelectronic therapies for individuals with chronic neurological conditions, particularly chronic migraines. Drawing its name from the Latin word for "to stay healthy," Salvia is committed to providing drug-free, effective, and side-effect-free solutions. The company leverages a team of experienced professionals, including entrepreneurs, engineers, and scientists, who have extensive backgrounds in the medical device industry. Salvia aims to make its innovative bioelectronic solutions widely accessible, addressing the needs of patients seeking alternative treatments for their conditions.

Castor is an international health-tech company that provides a cloud-based clinical data platform designed to streamline the clinical trial process for researchers globally. Founded by CEO Derk Arts, MD, Ph.D., the platform is utilized by over 50,000 researchers in 90 countries, supporting more than 4,000 studies across diverse therapeutic areas, including diabetes, cardiovascular disease, rare diseases, infectious diseases, and oncology. Castor's platform facilitates the collection and analysis of extensive data from both traditional and remote trials, having reached significant milestones such as 180 million data points and 2 million enrolled patients. The company's mission is to make research data reusable, thereby enabling AI-driven clinical trials and enhancing the overall impact of data within the medical research community.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

ViCentra, they like to keep things simple. ViCentra believe that if products are simple, look beautiful and deliver superb results, they’ll be more enjoyable to use and more likely to help people achieve great things. Creating brilliant products doesn’t end at the manufacturing line though – they also believe in the power of great customer experiences. From our offices in the Netherlands and UK, they’re creating healthcare products with this philosophy firmly in mind. They don’t design for patients – they design for people.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center focused on developing and manufacturing therapeutic proteins aimed at restoring blood clotting in patients experiencing severe bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X designed to work effectively in the presence of direct factor Xa anticoagulants like rivaroxaban, apixaban, and edoxaban. These anticoagulants are widely used for preventing and treating thrombosis and stroke but can lead to dangerous bleeding as a side effect. PseudoXa addresses this critical issue by providing a means to stop and prevent bleeding, thereby enhancing the safety of anticoagulant therapies for millions of patients worldwide.

Happeo is a digital workplace platform that offers an advanced intranet solution for teams to manage knowledge and internal communications effectively. The platform features a template-based page builder, integrations, and a universal search functionality that simplifies access to various company tools. Happeo's user-friendly design makes it suitable for organizations of all sizes, with notable clients like Doctolib, GANT, and Marqeta utilizing its services to enhance team alignment and productivity. The platform supports internal communicators by managing calendars, files, conferencing, and projects, while also integrating with CRM and HR systems. Happeo aims to foster engagement and create a positive employee experience, achieving adoption rates that are three times higher than the industry average.

Quantum Motion Technologies is focused on developing universal quantum computers utilizing silicon-based, CMOS-compatible processes. The company aims to address key challenges in quantum computing, such as fault tolerance and qubit redundancy, by creating scalable architectural technologies. By leveraging complementary metal-oxide semiconductor processing, Quantum Motion strives to achieve greater qubit density, enabling the construction of large-scale quantum systems. This approach not only enhances the performance of quantum computers but also assists clients in the quantum technology sector in overcoming significant errors and critical challenges in quantum information processing.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Based in Cambridge, Massachusetts, the company utilizes proprietary platforms and biomarkers to create precision medicines targeting genetically validated disease-causing alterations. Its pipeline includes various treatments aimed at specific subtypes of ALS, such as therapies designed to restore dysfunctional cellular waste clearance, manage overactive neurons to prevent cell death, and eliminate toxic proteins. QurAlis aims to advance its antisense oligonucleotides and small molecule programs to address the most prevalent forms of ALS, ultimately working to halt disease progression and improve patient outcomes. The company was incorporated in 2016 and operates as a subsidiary of Q-State Biosciences, Inc.

Remote offers payroll, tax, HR, and compliance solutions tailored for distributed teams. The company has developed a recruiting platform that assists organizations of all sizes in hiring top talent globally. This platform enables human resource executives to recruit individuals without the risk of compliance issues. Additionally, it supports management in project allocation and payment processes, ultimately enhancing productivity and expanding the workforce within client organizations.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

Draupnir Bio intends to develop a new type of cholesterol-lowering medicine that prevents blood clots in the heart more effectively than the current medicine. The company is developing a platform for exploring the glycome to develop novel therapeutics, based on array technology, protein chemistry, and advanced carbohydrate chemistry. The company is able to synthesize, screen, and select highly potent and specific heparan sulfate glycomimetic drug candidates in cardiovascular, inflammatory, and infectious diseases.

Cashforce BV operates a sophisticated cash flow management and forecasting platform designed to enhance financial efficiency for businesses. Founded in 2013 and based in Antwerp, Belgium, with additional offices in New York, Amsterdam, Copenhagen, and London, the company serves various sectors, including wholesale and distribution, transportation, logistics, and manufacturing. Its platform offers users the ability to forecast cash flows across multiple companies, bank accounts, and currencies, allowing for early detection of potential cash shortages or surpluses. Cashforce distinguishes itself through seamless integration with various ERP and banking systems, enabling detailed transaction-level analysis. The platform also features an AI-based simulation engine that supports multiple cash flow scenarios and impact assessments, providing cash visibility to multinational corporations in over 120 countries. The company has formed a strategic alliance with Treasury Intelligence Solutions GmbH to further enhance its offerings.

EclecticIQ specializes in threat intelligence and cybersecurity solutions, offering technology and services that enhance the defense against cyber threats. The company develops platforms that integrate and analyze intelligence data from various sources, including open and commercial suppliers, as well as industry partnerships. This integration allows organizations to improve their detection, prevention, and response capabilities against adversaries. By embedding intelligence into cybersecurity frameworks, EclecticIQ aims to empower enterprises to effectively combat evolving cyber threats.

Urban Sports Club offers a flexible sports flatrate. The mission is to help people lead a more healthy and active lifestyle. Club members can choose from more than 50 types of sports – ranging from classic gym workout, swimming, yoga, or bouldering, to team sports, wellness and lots more – and more than 10.000 partner venues in Germany, France, Italy, Spain, Portugal and Belgium. Variety, flexible conditions as well as team sports and wellness are offered both for private customers and companies. Urban Sports GmbH was founded in 2012 by Moritz Kreppel and Benjamin Roth in Berlin, Germany. After two years of bootstrapping, the company secured an early-stage financing in 2015 and went on to acquire four of its German competitors, starting with Somuchmore in December, 2016. In January 2018, FITrate came on board, with INTERFIT following in December of the same year. OneFit joined the Urban Sports Club family in August of 2019.

CoEnzyme is a developer of therapies designed to treat orphan neurological disorders. The company develops a treatment to restore dysregulated CoEnzyme A metabolism through its CoEnzyme metabolism platform, enabling physicians to address the profound unmet medical needs.

Withlocals is an online marketplace established in 2013 that specializes in personalized travel experiences. The platform offers over 1,200 customizable and private tours led by approximately 900 verified local hosts across various international cities, primarily in Europe and Asia. Withlocals aims to connect people and cultures through travel, allowing travelers to engage with destinations in an authentic manner, guided by locals who provide insights and experiences off the beaten path. The marketplace facilitates direct connections between hosts and tourists, making personalized travel accessible and affordable for a broad audience. Users can choose activities based on their interests, including food, music, and sports, ensuring a tailored experience that reflects their passions.

Aidence is a company that develops intelligent software aimed at improving the management of lung cancer. With a team of over 80 professionals, including data scientists, software engineers, and medical experts, Aidence has created its first clinical application, Veye Lung Nodules. This AI-driven solution assists in the management of pulmonary nodules identified in CT scans and is currently in use in routine clinical settings and lung cancer screening programs throughout Europe. The platform transforms complex data into practical information, enabling healthcare providers to enhance patient outcomes through quicker diagnoses, reduced misdiagnosis risks, and improved detection of early-stage lung cancer.

Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strong expertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates.

GeoPhy is a developer of an artificial intelligence-driven property analytics platform that leverages both traditional and alternative data sources to deliver instant and accurate valuations for commercial real estate. By utilizing machine learning, GeoPhy helps real estate professionals identify market opportunities and manage risks effectively. The platform provides valuable insights into commercial property values and the factors influencing them, allowing users to assess opportunities based on specific market criteria. Through its innovative approach, GeoPhy aims to enhance transparency and efficiency in the commercial real estate sector.

Polarsteps is a travel tracking platform that allows users to plan, track, and share their journeys in a streamlined manner. The app automatically records travel routes and key locations while users are on the move, ensuring that every moment is captured effortlessly. Once an internet connection is available, the app transfers this information, including photos, to a personalized Polarsteps page. This page displays the user's journey on a colorful world map, making it easy to share travel experiences with friends and family. By combining route tracking with a user-friendly interface, Polarsteps helps travelers create lasting memories and personalized photo albums to share with others.

GitLab Inc. is a software development company that provides a comprehensive DevSecOps platform designed to enhance the software development lifecycle. Founded in 2011 and headquartered in San Francisco, California, GitLab offers its services through a single application, which includes tools for version control, continuous integration and deployment, code reviews, issue tracking, and collaboration. This unified platform allows organizations to efficiently plan, build, secure, and deploy software while ensuring visibility and control throughout the process. GitLab serves a diverse clientele, ranging from startups to large enterprises, with an estimated 30 million registered users globally. The company operates on an all-remote model, employing over 1,350 team members across more than 65 countries. GitLab is built on open-source principles and benefits from a vibrant community of developers, continuously driving innovations in the DevOps space.

Castor is an international health-tech company that provides a cloud-based clinical data platform designed to streamline the clinical trial process for researchers globally. Founded by CEO Derk Arts, MD, Ph.D., the platform is utilized by over 50,000 researchers in 90 countries, supporting more than 4,000 studies across diverse therapeutic areas, including diabetes, cardiovascular disease, rare diseases, infectious diseases, and oncology. Castor's platform facilitates the collection and analysis of extensive data from both traditional and remote trials, having reached significant milestones such as 180 million data points and 2 million enrolled patients. The company's mission is to make research data reusable, thereby enabling AI-driven clinical trials and enhancing the overall impact of data within the medical research community.

Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.The company's technology uses Vofatamab, a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3), enabling medical practitioners to treat patients with early stage and metastatic bladder cancer effectively.

OneFit is a fitness aggregator that provides users with access to a diverse range of gyms and studios through a single monthly membership. By offering an all-in-one sports membership, OneFit simplifies the fitness experience, allowing individuals to explore various workout options and facilities without the need for multiple memberships. This approach caters to the growing demand for flexibility and variety in fitness routines, enabling users to tailor their workouts to their preferences and schedule.

Shapeways, Inc. is a 3D printing marketplace and community that allows users to create, buy, and sell customized products across various categories, including art, fashion, home goods, gadgets, games, jewelry, DIY projects, miniatures, and gifts. Founded in 2008 and headquartered in New York, with additional offices in Eindhoven, Netherlands, and Seattle, Washington, Shapeways utilizes on-demand printing to ensure that each order is tailored to individual specifications. The platform not only facilitates the transformation of digital designs into physical products but also fosters a community where members can share ideas and access advanced 3D printing technology. By democratizing the creation process, Shapeways empowers users to launch their own businesses and sell products globally.

NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.

Health Value Creation is developing two surgical devices, a diagnostic tool and a trocar closure device. The first device helps prevent anastomotic leakages after bowel surgery by predicting the quality of the anastomosis during surgery, thereby reducing post-operative complications and lowering healthcare costs. The second device is a trocar closure device for faster, safer and more secure suturing after laparoscopic surgery, resulting in a reduction of the chances of wound herniation.

Withlocals is an online marketplace established in 2013 that specializes in personalized travel experiences. The platform offers over 1,200 customizable and private tours led by approximately 900 verified local hosts across various international cities, primarily in Europe and Asia. Withlocals aims to connect people and cultures through travel, allowing travelers to engage with destinations in an authentic manner, guided by locals who provide insights and experiences off the beaten path. The marketplace facilitates direct connections between hosts and tourists, making personalized travel accessible and affordable for a broad audience. Users can choose activities based on their interests, including food, music, and sports, ensuring a tailored experience that reflects their passions.

GitLab Inc. is a software development company that provides a comprehensive DevSecOps platform designed to enhance the software development lifecycle. Founded in 2011 and headquartered in San Francisco, California, GitLab offers its services through a single application, which includes tools for version control, continuous integration and deployment, code reviews, issue tracking, and collaboration. This unified platform allows organizations to efficiently plan, build, secure, and deploy software while ensuring visibility and control throughout the process. GitLab serves a diverse clientele, ranging from startups to large enterprises, with an estimated 30 million registered users globally. The company operates on an all-remote model, employing over 1,350 team members across more than 65 countries. GitLab is built on open-source principles and benefits from a vibrant community of developers, continuously driving innovations in the DevOps space.

Scenic Biotech is a biotechnology company focused on developing innovative genomics and immunotherapy technologies aimed at addressing severe diseases, including cancer and rare genetic disorders. The company's approach involves identifying genetic suppressors, which are genes that can counteract the effects of disease-causing mutations, thus serving as new drug targets. By leveraging its advanced technology, Scenic Biotech enables scientists to rapidly identify and validate these novel drug targets, facilitating the development of disease-modifying therapeutics. This targeted strategy not only enhances the understanding of genetic influences on diseases but also aims to improve treatment outcomes for affected patients.

Blendle is a digital media platform that allows readers to purchase articles from various Dutch and Belgian newspapers and magazines, including prominent publications like the Economist. Users can buy individual articles for prices ranging from €0.10 to €0.30, and they are presented with a selection of recommendations similar to social media feeds. New users are provided with an initial credit of €2.50 to explore the platform. The service includes a brief refund window for article purchases, after which Blendle retains a 30% commission on sales. By offering a pay-per-article model, Blendle aims to enhance access to quality journalism and cater to readers' preferences through personalized recommendations.

Bloomon B.V., founded in 2014 and headquartered in Amsterdam, Netherlands, operates an online retail platform specializing in flower delivery across Europe. The company emphasizes a direct-to-consumer model, sourcing flowers directly from growers to ensure quality. Bloomon offers a subscription service allowing customers to conveniently arrange their orders online, with the flexibility to pause, change, or cancel deliveries without any commitment. This approach enables users to create customized packaging with fresh flowers, enhancing their overall experience. Focused on client satisfaction and product quality, Bloomon prioritizes service over competition in the online flower market.

GitLab Inc. is a software development company that provides a comprehensive DevSecOps platform designed to enhance the software development lifecycle. Founded in 2011 and headquartered in San Francisco, California, GitLab offers its services through a single application, which includes tools for version control, continuous integration and deployment, code reviews, issue tracking, and collaboration. This unified platform allows organizations to efficiently plan, build, secure, and deploy software while ensuring visibility and control throughout the process. GitLab serves a diverse clientele, ranging from startups to large enterprises, with an estimated 30 million registered users globally. The company operates on an all-remote model, employing over 1,350 team members across more than 65 countries. GitLab is built on open-source principles and benefits from a vibrant community of developers, continuously driving innovations in the DevOps space.

NightBalance B.V. is a company established by alumni of TU Delft, originating from research conducted at the Delft University of Technology in 2007 focused on enhancing positional therapy aids. Founded in 2009, NightBalance specializes in the development of the Sleep Position Trainer, a smart therapeutic device designed to address sleep apnea. This innovative therapy monitors patients' sleep behavior and actively prevents positional obstructive sleep apnea, allowing individuals to achieve more comfortable and restful sleep.

GeoPhy is a developer of an artificial intelligence-driven property analytics platform that leverages both traditional and alternative data sources to deliver instant and accurate valuations for commercial real estate. By utilizing machine learning, GeoPhy helps real estate professionals identify market opportunities and manage risks effectively. The platform provides valuable insights into commercial property values and the factors influencing them, allowing users to assess opportunities based on specific market criteria. Through its innovative approach, GeoPhy aims to enhance transparency and efficiency in the commercial real estate sector.

EclecticIQ specializes in threat intelligence and cybersecurity solutions, offering technology and services that enhance the defense against cyber threats. The company develops platforms that integrate and analyze intelligence data from various sources, including open and commercial suppliers, as well as industry partnerships. This integration allows organizations to improve their detection, prevention, and response capabilities against adversaries. By embedding intelligence into cybersecurity frameworks, EclecticIQ aims to empower enterprises to effectively combat evolving cyber threats.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Crowdynews operates an AI-driven platform that curates social media content for the news media market. The platform automates the integration of real-time, relevant, and safe user-generated content from various social media channels, such as Twitter, Facebook, Instagram, and YouTube, alongside traditional editorial content. By leveraging artificial intelligence and natural language processing, Crowdynews enables media organizations and brands to enhance their storytelling capabilities, incorporating diverse elements like photos, videos, and eyewitness accounts. This approach not only enriches the audience's experience but also aims to drive engagement, improve conversion rates, and increase revenue for its clients.

Wercker is a platform designed to facilitate the rapid development, building, and deployment of containerized applications and microservices. It provides a SaaS-based cloud code deployment solution that automates the processes of testing and deploying code. With features that include a local command-line interface (CLI) and an API, Wercker enables developers and businesses to achieve continuous integration and continuous delivery (CI/CD) objectives efficiently. By streamlining these processes, Wercker aims to enhance the productivity of developers, allowing them to focus on innovation and the swift execution of projects.

ViCentra, they like to keep things simple. ViCentra believe that if products are simple, look beautiful and deliver superb results, they’ll be more enjoyable to use and more likely to help people achieve great things. Creating brilliant products doesn’t end at the manufacturing line though – they also believe in the power of great customer experiences. From our offices in the Netherlands and UK, they’re creating healthcare products with this philosophy firmly in mind. They don’t design for patients – they design for people.

InteRNA Technologies B.V. is a biotechnology company focused on the development of microRNA (miRNA)-based therapeutics for cancer treatment. The company's innovative approach leverages the unique properties of miRNAs to target previously undruggable pathways involved in cancer initiation, progression, and metastasis. By utilizing advanced techniques such as massively parallel sequencing and proprietary bioinformatics, InteRNA analyzes and validates miRNA sequences to enhance drug efficacy and reduce resistance to existing therapies. Founded in 2006, the company operates from Nijmegen, the Netherlands, and has a dedicated research and development center in Utrecht. Recently, InteRNA has secured additional equity financing to advance its lead program for melanoma treatment, demonstrating its commitment to developing novel solutions in oncology.

Audion Therapeutics BV is a biopharmaceutical company based in Amsterdam, Netherlands, focused on the discovery, development, and commercialization of therapies for ear-related diseases, particularly hearing loss. Founded in 2008, the company is engaged in small molecule drug discovery aimed at regenerating inner hair cells, which are vital for hearing. Audion Therapeutics leverages a unique approach by targeting a protein complex known as gamma-secretase to address sensorineural hearing loss, often associated with aging. The company's intellectual property portfolio comprises new drug molecules, advanced delivery systems, and innovative tools for research in hearing and hearing loss.

Bloomon B.V., founded in 2014 and headquartered in Amsterdam, Netherlands, operates an online retail platform specializing in flower delivery across Europe. The company emphasizes a direct-to-consumer model, sourcing flowers directly from growers to ensure quality. Bloomon offers a subscription service allowing customers to conveniently arrange their orders online, with the flexibility to pause, change, or cancel deliveries without any commitment. This approach enables users to create customized packaging with fresh flowers, enhancing their overall experience. Focused on client satisfaction and product quality, Bloomon prioritizes service over competition in the online flower market.

Shapeways, Inc. is a 3D printing marketplace and community that allows users to create, buy, and sell customized products across various categories, including art, fashion, home goods, gadgets, games, jewelry, DIY projects, miniatures, and gifts. Founded in 2008 and headquartered in New York, with additional offices in Eindhoven, Netherlands, and Seattle, Washington, Shapeways utilizes on-demand printing to ensure that each order is tailored to individual specifications. The platform not only facilitates the transformation of digital designs into physical products but also fosters a community where members can share ideas and access advanced 3D printing technology. By democratizing the creation process, Shapeways empowers users to launch their own businesses and sell products globally.

Crowdynews operates an AI-driven platform that curates social media content for the news media market. The platform automates the integration of real-time, relevant, and safe user-generated content from various social media channels, such as Twitter, Facebook, Instagram, and YouTube, alongside traditional editorial content. By leveraging artificial intelligence and natural language processing, Crowdynews enables media organizations and brands to enhance their storytelling capabilities, incorporating diverse elements like photos, videos, and eyewitness accounts. This approach not only enriches the audience's experience but also aims to drive engagement, improve conversion rates, and increase revenue for its clients.

Aito specializes in developing advanced touch interface technology that enhances user interaction through tactile feedback. The company focuses on patented Piezo Sensing and Haptics technology, which enables the detection of finger positions on user interfaces. Aito's solutions include configurable integrated circuits that facilitate the creation of physical user interfaces, such as buttons, touchpads, and touch screens. This innovation allows consumer electronics brands to improve their products, including smartphones and car infotainment systems, by providing a more engaging and differentiated user experience in a competitive marketplace.

NPEX operates an online trading platform that connects entrepreneurs with investors, facilitating the trading of securities. The platform is designed to enhance the financing process by offering features such as interest on bonds and access to clear, comprehensive documentation for investors. Additionally, NPEX aids entrepreneurs in increasing brand awareness through media exposure, supporting them in raising funds and issuing stock and bonds. This secure platform provides a streamlined environment for trading, benefiting both companies seeking capital and investors looking for opportunities.

Shapeways, Inc. is a 3D printing marketplace and community that allows users to create, buy, and sell customized products across various categories, including art, fashion, home goods, gadgets, games, jewelry, DIY projects, miniatures, and gifts. Founded in 2008 and headquartered in New York, with additional offices in Eindhoven, Netherlands, and Seattle, Washington, Shapeways utilizes on-demand printing to ensure that each order is tailored to individual specifications. The platform not only facilitates the transformation of digital designs into physical products but also fosters a community where members can share ideas and access advanced 3D printing technology. By democratizing the creation process, Shapeways empowers users to launch their own businesses and sell products globally.

ViCentra, they like to keep things simple. ViCentra believe that if products are simple, look beautiful and deliver superb results, they’ll be more enjoyable to use and more likely to help people achieve great things. Creating brilliant products doesn’t end at the manufacturing line though – they also believe in the power of great customer experiences. From our offices in the Netherlands and UK, they’re creating healthcare products with this philosophy firmly in mind. They don’t design for patients – they design for people.

Sapiens Steering Brain Stimulation GmbH is an emerging medical device company whose mission is to deliver superior solutions for deep brain stimulation (DBS) therapy. Sapiens' ambition is to provide a unique, high-resolution, and MRI- compatible DBS system that will improve patient comfort and therapeutic outcome, initially for patients with Parkinson's disease. Sapiens, with offices in Eindhoven, the Netherlands and Munich, Germany, is founded in 2011 as a spin-out of Royal Philips Electronics. Its steering brain stimulation (SBS) system and image-guided programming are based upon patented technologies.

Lanthio Pharma B.V. is a biopharmaceutical company based in Groningen, the Netherlands, specializing in the discovery and development of lantipeptide drugs aimed at treating conditions such as fibrosis, stroke, heart failure, and multiple sclerosis. The company employs its proprietary lanthionine-peptide drug discovery technology, LanthioPep™, to create novel peptide therapeutics that exhibit enhanced resistance to peptidase degradation and high receptor specificity. Among its product pipeline are LP2, designed to target fibrosis; PanCyte, intended for ischemic stroke recovery and related conditions; a Lanthi-apelin agonist for various organ systems; and Lanthi-galanin for multiple sclerosis. Founded in 2010, Lanthio Pharma operates as a subsidiary of Morphosys AG, focusing on generating stable, peptidase-resistant peptides that possess high intrinsic activity for several G-protein-coupled receptor targets.

NPEX operates an online trading platform that connects entrepreneurs with investors, facilitating the trading of securities. The platform is designed to enhance the financing process by offering features such as interest on bonds and access to clear, comprehensive documentation for investors. Additionally, NPEX aids entrepreneurs in increasing brand awareness through media exposure, supporting them in raising funds and issuing stock and bonds. This secure platform provides a streamlined environment for trading, benefiting both companies seeking capital and investors looking for opportunities.

Robin Radar Systems B.V., based in The Hague, the Netherlands, specializes in developing radar systems for bird detection and tracking. The company offers several products, including a 2D Mobile system that detects bird presence, number, location, direction, speed, and route over distances of up to 20 kilometers; a 3D Fixed system that provides similar data up to 10 kilometers; and a 3D Flex system that combines horizontal S-band radar with flexible frequency modulated continuous wave radar. Their Military XL system is designed to assist air forces in preventing bird strikes. Robin Radar Systems also offers essential support services such as testing, training, documentation, and maintenance. Established in 2010 as a spin-off from the Dutch Research Institute for Applied Science (TNO), the company has access to advanced radar technology developed for bird tracking since the 1970s. Their innovative solutions aim to enhance safety and sustainability for wind farms, airports, and other operations while minimizing environmental impacts.

ProFibrix B.V., a biotech company, creates, develops, and markets products for the hemostasis and regenerative medicine markets. Its products include Fibrocaps, a dry powder topical hemostat and tissue sealant based on a mixture of fibrinogen and thrombin, which stops acute and severe bleeding during surgery or in connection with trauma injury. The company also provides a sterilized single-use delivery device to deliver Fibrocaps to the target tissue area without the need to manipulate the wound in a surgical environment. It offers its products based on human fibrinogen, a natural blood protein for haemostasis, blood clotting, and tissue repair and healing. ProFibrix B.V. was founded in 2004